SCHEMBL5544007

SCHEMBL5544007

[CH2]c1ccc(Oc2c(Cl)cccc2Cl)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.41
POLB P06746 1/20 0.41
BCHE P06276 6/20 0.37
ACHE P22303 6/20 0.37
RHEB Q15382 1/20 0.36
RARG P13631 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
DPP4 P27487 1/20 0.35
KMT2A Q03164 1/20 0.34
THRA P10827 1/20 0.34
THRB P10828 1/20 0.34
APEX1 P27695 1/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2A6 P11509 1/20 0.33
LPAR1 Q92633 1/20 0.33
LPAR5 Q9H1C0 1/20 0.33
CRHBP P24387 1/20 0.32
CRHR2 Q13324 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5543172 0.81 CYP2C9 (0.41) MAPTSMN1; SMN2KMT2ATHRATHRB
SCHEMBL9645022 0.79 LTA4H (0.52) MAPTPOLBRHEBRARGDPP4
SCHEMBL23061547 0.78 MAOA (0.56) MAPTPOLBBCHEACHESMN1; SMN2
SCHEMBL11428693 0.78 TEAD4 (0.45) MAPTPOLBBCHEACHESMN1; SMN2
SCHEMBL5543365 0.77 DPP4 (0.46) MAPTPOLBSMN1; SMN2DPP4KMT2A
SCHEMBL2752619 0.74 RHEB (0.36) MAPTPOLBBCHEACHERHEB
SCHEMBL5539624 0.74 LPAR1 (0.40) MAPTPOLBLPAR1LPAR5
SCHEMBL5535849 0.74 AR (0.41) MAPTCYP1A2CYP2A6LPAR1LPAR5
SCHEMBL31448041 0.74 BCHE (0.47) MAPTPOLBBCHEACHEDPP4
Nitrogen SCHEMBL23671381 0.74 BCHE (0.50) MAPTPOLBBCHEACHESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885POLB 1637/4885BCHE 4833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.